EN DE

Apollo Hospitals Enterprise Limited (APOLLOHOSP) Fair Value & Analysis

Healthcare · IN · Market cap ₹1.3T

AH Apollo Hospitals Enterprise Limited APOLLOHOSP · NSE
Price₹8,975
Fair Value₹5,234
Upside-41.7%
Quality66/100
Watch Apollo Hospitals Enterprise Limited for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Thin margins · 7.7% net margin
Low debt · generates free cash flow
0.23% dividend yield
Mixed vs. peers (7/14)
Moderate moat 58/100
Evidence: High Range ₹2,831 – ₹7,808 Share as image

Fair value as of: Jul 12, 2026

From 26 valuation models · updated 26 days ago

Fair value updated Jul 12, 2026, revised from ₹2,967 to ₹5,234 (+76.4%) since Jun 24, 2026. Share price +1.6% over the past month.

A solid business, but screening 42% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (₹7,808). The favourable scenario is already priced in.
  • The model range is unusually wide (₹2,831 to ₹7,808). The outcome hinges heavily on assumptions, so read the point estimate with caution.
  • Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

₹9,050 ₹2,942 Fair Value ₹5,234 Apr 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.

How to read this chart

60‑month range ₹2,942 – ₹9,050 · fair‑value band ₹2,831 – ₹7,808 · the ₹8,975 price screens above the ₹5,234 fair value. Dashed = 300-day average. As of Jul 12, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Apollo Hospitals Enterprise Limited (APOLLOHOSP) currently trades at ₹8,975, while our model-based Fair Value estimate is ₹5,234, implying the stock looks roughly 41.7% overvalued today. We read business quality at 66/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Apollo Hospitals Enterprise Limited generated revenue of ₹252B at a net margin of 7.7%. Revenue grew 18.1% year over year. It earns a return on equity of 21.5%. Net debt stands at ₹73.8B. Fundamentals as of Jul 12, 2026

Our scenario range runs from ₹2,831 (bear case) to ₹7,808 (bull case); at ₹8,975, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 34% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -42%, APOLLOHOSP screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model BearBaseBull Evidence
Highest evidence
Growth DCF ₹646.72 ₹1,488 ₹2,907 80
Residual Income ₹959.61 ₹1,330 ₹7,511 76
Rev-Margin DCF ₹1,471 ₹3,096 ₹5,391 74
All 26 models by family
DCF Models
FCF DCF ₹667.33 ₹1,335 ₹3,106 38
Owner Earnings ₹820.29 ₹1,851 ₹3,948 31
5Y Revenue Exit ₹1,471 ₹3,197 ₹5,734 39
5Y EBITDA Exit ₹1,879 ₹4,111 ₹7,146 41
5Y P/E Exit ₹1,515 ₹3,295 ₹5,507 38
10Y Revenue Exit ₹1,157 ₹2,783 ₹5,682 36
10Y EBITDA Exit ₹1,517 ₹3,502 ₹6,995 37
10Y P/E Exit ₹1,261 ₹2,860 ₹5,471 35
Earnings-Based
Graham-Dodd ₹918.29 ₹5,517 ₹7,689 54
Lynch FV ₹1,573 ₹2,247 ₹2,921 50
PEG = 1.0 ₹1,573 ₹2,247 ₹2,921 46
EPV ₹1,463 ₹1,737 ₹1,981 59
Dividend Discount
Gordon GGM ₹192.40 ₹420.04 ₹706.74 70
DDM Multi-Stage ₹192.40 ₹344.08 ₹437.75 61
Multiples
P/E Multiple ₹2,026 ₹2,701 ₹3,376 63
P/S Multiple ₹1,722 ₹2,296 ₹2,870 58
P/B Multiple ₹1,483 ₹1,978 ₹2,472 55
EV/EBIT ₹2,625 ₹3,531 ₹4,436 53
EV/EBITDA ₹2,465 ₹3,317 ₹4,169 54
EV/Revenue ₹1,740 ₹2,524 ₹3,309 43
Asset-Based
NCAV (Graham) ₹329.66 ₹441.75 ₹659.33 50
Growth DCF
Growth DCF ₹646.72 ₹1,488 ₹2,907 80
Rev-Margin DCF ₹1,471 ₹3,096 ₹5,391 74
Economic Profit
Residual Income ₹959.61 ₹1,330 ₹7,511 76
ROIC Compounder ₹1,811 ₹2,695 ₹3,973 72
Growth Earnings
Growth-Adj P/E ₹2,235 ₹3,193 ₹4,150 68

Widest divergence: Growth Earnings (₹3,193) versus Dividend Discount (₹344.08). Highest evidence: Growth DCF (80).

Key figures & financial health

Revenue (TTM) ₹252B
Revenue growth (YoY) +18.1%
Net margin 7.7%
Return on equity 21.5%
Free cash flow ₹7.1B FY2026
P/E ratio 65.4
More key figures
Operating margin 11.9%
EPS (TTM) ₹135.27
Dividend yield 0.2%
EPS growth (YoY) +35.6%
Net debt ₹73.8B FY2026

Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 66/100

Of which business quality 57 · Market factors (momentum, volatility) 79

Profitability 65
Margins and returns on capital today
Quality Growth 70
Are margins and returns improving?
Cashflow 32
Earnings quality: real cash, not paper profit
Fin. Strength 58
Balance sheet, leverage, solvency risk
Investment 38
Disciplined investing over empire-building
Low Volatility 96
Calm price path (market factor)
Momentum 67
Price trend over the last 3–12 months (market factor)
52W Momentum 80
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Apollo Hospitals Enterprise Limited, together with its subsidiaries, provides healthcare services in India. It operates through Healthcare Services, Retail Health & Diagnostics, Digital Health & Pharmacy Distribution, and Others segments. The company's healthcare facilities comprise primary, secondary, and tertiary care, as well as specialty facilities.

Full company description

Apollo Hospitals Enterprise Limited, together with its subsidiaries, provides healthcare services in India. It operates through Healthcare Services, Retail Health & Diagnostics, Digital Health & Pharmacy Distribution, and Others segments. The company's healthcare facilities comprise primary, secondary, and tertiary care, as well as specialty facilities. It offers services in cardiac sciences, oncology, neurosciences, gastroenterology, orthopedics, urology, organ transplantation, pulmonology, obstetrics and gynecology, internal medicine, vascular surgery, pediatrics, cosmetology, emergency medicine, bariatric surgery, general surgery, colorectal surgery, dentistry, nephrology, dermatology, endocrinology, preventive medicine, interventional radiology, ophthalmology, and integrative medicine, as well as robotic surgery and genomics. The company also provides project consultancy, medical educational institutes, Medvarsity for e-learning, and research services, as well as acts as an agent for life, general, and health insurance. In addition, it operates hospitals, pharmacies, primary care clinics, and diagnostic centers; short stay facilities, boutique birthing centers, multi-specialty clinics, dental and dialysis facilities, and preventive care; day surgery, diabetes management, and cradle and fertility centers; and Apollo 24/7, a digital health mobile platform that provides teleconsultations, online pharmacy deliveries, home diagnostics, and insurance services. Further, the company engages in the business of bio-banking of tissues. It serves patients, corporate clients, and the government and public sectors. Apollo Hospitals Enterprise Limited was incorporated in 1979 and is based in Chennai, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Apollo Hospitals Enterprise Limited reported revenue of ₹252B in FY2026 versus ₹147B in FY2022, a compound +14.5%/yr. Reported net income was ₹19.4B in FY2026, compounding +16.5%/yr from FY2022.

Growth Quality 81/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2026)
₹252B
Latest YoY
+15.8%
Avg. growth/yr (3Y)
+14.9%
Avg. growth/yr (5Y)
+19.0%
Avg. growth/yr (21Y)
+18.9%
Revenue +14.5%/yr
FY22 ₹147B
FY23 ₹166B
FY24 ₹191B
FY25 ₹218B
FY26 ₹252B
Net income +16.5%/yr
FY22 ₹10.6B
FY23 ₹8.2B
FY24 ₹9.0B
FY25 ₹14.5B
FY26 ₹19.4B

APOLLOHOSP screens 42% overvalued. Compare with HCA Healthcare, Inc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Apollo Hospitals Enterprise Limited Fair Value". https://www.fairvalue-calculator.com/stock/APOLLOHOSP

Earlier news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.

Peer Group

Medical Care Facilities · 262 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 66 · Top 25%
Fair Value upside −42% · Below median
Return on equity (TTM) 22% · Top 25%
Return on assets 8% · Top 25%
Net margin (TTM) 8% · Above median
Operating margin (TTM) 12% · Above median
Revenue growth 18% · Top 25%
Dividend yield (TTM) 0.2% · Bottom 25%
Debt / equity 0.26× · Higher than median

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/E (TTM) 65.4× · Pricier than 75% of peers
P/B 13.41× · Pricier than 75% of peers
P/S (TTM) 5.04× · Pricier than 75% of peers
P/FCF 1.9× · Cheaper than median
EV/EBITDA 34.1× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 23
FUTURE 91 · sector 24
PAST 86 · sector 30
HEALTH 87 · sector 90
DIVIDEND 5 · sector 38

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $378.85 $554.93 +46%
Fresenius SE FRE €41.73 €32.15 -23%
Dr. Sulaiman Al Habib Medical Services Group 4013 235.00 SAR 112.37 SAR -52%
IHH Healthcare Berhad, an investment holding company, Q0F 2.76 SGD 1.28 SGD -54%
Tenet Healthcare Corporation THC $194.91 $338.05 +73%
Rede D'Or São Luiz S.A RDOR3 R$36.01 R$47.31 +31%
DaVita Inc DVA $231.61 $255.97 +11%
Fresenius Medical Care AG FMS $24.68 $45.60 +85%
Aier Eye Hospital Group 300015 ¥8.68 ¥7.67 -12%
Max Healthcare Institute Limited MAXHEALTH ₹1,103 ₹284.87 -74%

Compare Apollo Hospitals Enterprise Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Apollo Hospitals Enterprise Limited (APOLLOHOSP) overvalued or undervalued?
As of Jul 12, 2026, our model estimates a fair value of ₹5,234 versus a price of ₹8,975, about −42% (overvalued).
What is the fair value of APOLLOHOSP?
Our model-based fair value for Apollo Hospitals Enterprise Limited is ₹5,234 (as of Jul 12, 2026), built from audited fundamentals. The current price is ₹8,975.
What is the quality score of APOLLOHOSP?
Apollo Hospitals Enterprise Limited has a Quality Score of 66/100. It combines two groups: business quality (profitability, growth, cash flow, balance-sheet strength) and market factors (price momentum, distance to the 52-week high, volatility). Both subtotals are shown separately in the detail view.
What is the revenue of Apollo Hospitals Enterprise Limited (APOLLOHOSP)?
Apollo Hospitals Enterprise Limited reported trailing-twelve-month revenue of about ₹252B (latest available figure, as of Jul 12, 2026).
What is the net profit margin of APOLLOHOSP?
The net profit margin of Apollo Hospitals Enterprise Limited is about 7.7%, meaning it keeps roughly 7.7% of revenue as net income. Based on the latest reported figures.
Does Apollo Hospitals Enterprise Limited pay a dividend?
Apollo Hospitals Enterprise Limited currently shows a dividend yield of about 0.24% relative to its recent price (as of Jul 12, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Apollo Hospitals Enterprise Limited and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.